Log in to save to my catalogue

Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degener...

Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degener...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2620768833

Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

About this item

Full title

Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Graefe's archive for clinical and experimental ophthalmology, 2022-06, Vol.260 (6), p.1857-1865

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Background/purpose
Observation of choroidal thickness after anti-vascular endothelial growth factor (VEGF) therapy may be important for the ideal management of neovascular age-related macular degeneration (AMD). This study investigated changes in subfoveal choroidal thickness (SCT) during loading doses of intravitreal injections of brolucizumab...

Alternative Titles

Full title

Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2620768833

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2620768833

Other Identifiers

ISSN

0721-832X

E-ISSN

1435-702X

DOI

10.1007/s00417-021-05517-1

How to access this item